Cormorant Asset Management’s Parabilis Medicines Inc PBLS Stock Holding History

Cormorant Asset Management’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$126M	Buy	+4,615,612	New	+$128M	6.47%	3

Other funds holding PBLS

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Cormorant Asset Management's PBLS Position: Q2 2026 in Review

Cormorant Asset Management opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 4,615,612 shares worth $126M. The stake represents 6.47% of the portfolio and ranks #3 among its holdings.

79 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

Cormorant Asset Management held 4,615,612 shares of Parabilis Medicines Inc worth $126M as of Q2 2026.
Parabilis Medicines Inc was a new Cormorant Asset Management position in Q2 2026.
Parabilis Medicines Inc made up 6.47% of Cormorant Asset Management's portfolio in Q2 2026, its #3 holding.
79 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.